Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.piramalpharma.com | |
Market Cap | 17,052.80 Cr. | |
Enterprise Value(EV) | 20,920.82 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -0.25 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.54 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 58.61 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 2.20 | Calculated using Price: 128.90 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 132.29 Cr. | 1,322,948,130 Shares |
FaceValue | 10 | |
About Piramal Pharma Ltd. | ||
The company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across many global facilities and a global distribution network in hundreds of countries. It includes PPS, PCC and the India Consumer Healthcare business, selling over-the-counter products. |
1 Day |
|
+5.35% |
1 Week |
|
+6.66% |
1 Month |
|
-5.88% |
3 Month |
|
-6.56% |
6 Month |
|
+33.09% |
1 Year |
|
+103.44% |
2 Year |
|
|
5 Year |
|
|
10 Year |
|
3 years | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 14.9 | 6.11 | -2.77 | |
Return on Capital Employed (%) | 13.06 | 7.1 | 1.95 | |
Return on Assets (%) | 7.76 | 3.2 | -1.37 |
Particulars | 4 years | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 5,605 | 6,697 | 6,774 | 7,758 | |
Non Curr. Liab. | 2,560 | 2,903 | 3,812 | 3,032 | |
Curr. Liab. | 2,591 | 3,118 | 3,851 | 3,597 | |
Minority Int. | |||||
Equity & Liab. | 10,756 | 12,717 | 14,437 | 14,386 | |
Non Curr. Assets | 7,007 | 8,565 | 9,593 | 9,432 | |
Curr. Assets | 3,749 | 4,152 | 4,843 | 4,954 | |
Misc. Exp. not W/O | |||||
Total Assets | 10,756 | 12,717 | 14,437 | 14,386 |
Particulars | 4 years | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 6,315 | 6,559 | 7,082 | 7,782 | |
Other Income | 164 | 276 | 225 | 174 | |
Total Income | 6,479 | 6,835 | 7,307 | 7,956 | |
Total Expenditure | -4,887 | -5,609 | -6,453 | -6,765 | |
PBIDT | 1,592 | 1,225 | 853 | 1,191 | |
Interest | -163 | -198 | -344 | -439 | |
Depreciation | -545 | -586 | -677 | -729 | |
Taxation | -114 | -109 | -66 | -80 | |
Exceptional Items | 18 | -15 | -7 | -32 | |
PAT | 835 | 376 | -186 | -89 | |
Minority Interest | |||||
Share Associate | 55 | ||||
Other Related Items | |||||
Consolidated Net Profit | 835 | 376 | -186 | -33 | |
Adjusted EPS | 8 | 3 | -2 | 0 |
Particulars | 3 years | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 598 | 766 | 484 | |
Cash Fr. Inv. | -4,480 | -1,812 | -1,339 | |
Cash Fr. Finan. | 3,977 | 794 | 818 | |
Net Change | 94 | -251 | -37 | |
Cash & Cash Eqvt | 262 | 85 | 53 |
Mon, 18 Mar 2024
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for HDFC Mutual Fund |
Wed, 13 Mar 2024
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Deutsche Bank AG |
Wed, 13 Mar 2024
Intimation For Change In Domain Name Of The Website Of The Company Intimation for change in domain name of the website of the Company |
Thu, 28 Mar 2024 |
Higher Delivery Quantity |
Higher Trade Quantity |
Higher Trade and Delivery Quantity |
Close Crossing Last Week High |
Closing Above Previous High |